These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31638456)

  • 41. An atypical form of Bietti crystalline dystrophy.
    Rossi S; Testa F; Li A; Iorio VD; Zhang J; Gesualdo C; Corte MD; Chan CC; Fielding Hejtmancik J; Simonelli F
    Ophthalmic Genet; 2011 Jun; 32(2):118-21. PubMed ID: 21385027
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical and angiographic characteristics of Bietti's corneoretinal dystrophy: a case study of an 8-year-old girl].
    Chaker N; Mghaieth F; Baccouri R; Merdassi A; Turki F; El Matri L
    J Fr Ophtalmol; 2007 Jan; 30(1):39-43. PubMed ID: 17287670
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Uncovering the role of ferroptosis in Bietti crystalline dystrophy and potential therapeutic strategies.
    Shen C; Yang Q; Chen K; Ma H; Wang X; Tong J; Shen Y; Cui H
    Cell Commun Signal; 2024 Jul; 22(1):359. PubMed ID: 38992691
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An In-Depth Single-Gene Worldwide Carrier Frequency and Genetic Prevalence Analysis of CYP4V2 as the Cause of Bietti Crystalline Dystrophy.
    Hanany M; Yang RR; Lam CM; Beryozkin A; Sundaresan Y; Sharon D
    Transl Vis Sci Technol; 2023 Feb; 12(2):27. PubMed ID: 36795063
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel mutations in
    Meng XH; He Y; Zhao TT; Li SY; Liu Y; Yin ZQ
    Mol Vis; 2019; 25():654-662. PubMed ID: 31741654
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular analysis and phenotypic study in 14 Chinese families with Bietti crystalline dystrophy.
    Yin H; Jin C; Fang X; Miao Q; Zhao Y; Chen Z; Su Z; Ye P; Wang Y; Yin J
    PLoS One; 2014; 9(4):e94960. PubMed ID: 24739949
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PREDICTED PROTEIN STRUCTURE VARIATIONS INDICATE THE CLINICAL PRESENTATION OF CYP4V2-RELATED BIETTI CRYSTALLINE DYSTROPHY.
    Chan LW; Sung YC; Wu DC; Chen CY; Yang CH; Yang CM; Chen PL; Chen TC
    Retina; 2022 Apr; 42(4):797-806. PubMed ID: 34923510
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Screening for mutations in CYP4V2 gene in Japanese patients with Bietti's crystalline corneoretinal dystrophy.
    Wada Y; Itabashi T; Sato H; Kawamura M; Tada A; Tamai M
    Am J Ophthalmol; 2005 May; 139(5):894-9. PubMed ID: 15860296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Choroidal findings in Bietti's crystalline dystrophy.
    Zerbib J; Ores R; Querques G; Bouzitou-Mfoumou R; Souied EH
    Retin Cases Brief Rep; 2014; 8(2):130-1. PubMed ID: 25372328
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comprehensive screening of
    Zhang X; Xu K; Dong B; Peng X; Li Q; Jiang F; Xie Y; Tian L; Li Y
    Mol Vis; 2018; 24():700-711. PubMed ID: 30429639
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multimodal imaging of Bietti's crystalline dystrophy.
    Kumar V; Gadkar A
    Indian J Ophthalmol; 2018 Jul; 66(7):1024-1026. PubMed ID: 29941763
    [TBL] [Abstract][Full Text] [Related]  

  • 52. AAV-mediated gene-replacement therapy restores viability of BCD patient iPSC derived RPE cells and vision of Cyp4v3 knockout mice.
    Jia R; Meng X; Chen S; Zhang F; Du J; Liu X; Yang L
    Hum Mol Genet; 2023 Jan; 32(1):122-138. PubMed ID: 35925866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CYP4V2 in Bietti's crystalline dystrophy: ocular localization, metabolism of ω-3-polyunsaturated fatty acids, and functional deficit of the p.H331P variant.
    Nakano M; Kelly EJ; Wiek C; Hanenberg H; Rettie AE
    Mol Pharmacol; 2012 Oct; 82(4):679-86. PubMed ID: 22772592
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel CYP4V2 mutations associated with Bietti crystalline corneoretinal dystrophy in Chinese patients.
    Tian R; Wang SR; Wang J; Chen YX
    Int J Ophthalmol; 2015; 8(3):465-9. PubMed ID: 26085992
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Bietti Crystalline Dystrophy Mouse Model Shows Increased Sensitivity to Light-Induced Injury.
    Ma Z; Jiao X; Agbaga MP; Anderson RE; Qian H; Li Q; Dong L; Hejtmancik JF
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361898
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bietti's crystalline corneoretinal dystrophy: a cross-sectional study.
    Mataftsi A; Zografos L; Millá E; Secrétan M; Munier FL
    Retina; 2004 Jun; 24(3):416-26. PubMed ID: 15187665
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vivo genome editing via CRISPR/Cas9-mediated homology-independent targeted integration for Bietti crystalline corneoretinal dystrophy treatment.
    Meng X; Jia R; Zhao X; Zhang F; Chen S; Yu S; Liu X; Dou H; Feng X; Zhang J; Wang N; Xu B; Yang L
    Nat Commun; 2024 May; 15(1):3773. PubMed ID: 38710738
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural and functional phenotypic features and molecular analysis of Indian patients with Bietti crystalline dystrophy.
    Ratra D; Chattree S; Raviselvan M; Pradhan A; Giridhar S
    Indian J Ophthalmol; 2022 Jul; 70(7):2526-2532. PubMed ID: 35791149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genotype phenotype analysis of Bietti's crystalline dystrophy in patients with CYP4V2 mutations.
    Lai TY; Ng TK; Tam PO; Yam GH; Ngai JW; Chan WM; Liu DT; Lam DS; Pang CP
    Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5212-20. PubMed ID: 17962476
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bietti's crystalline dystrophy: genotyping and deep qualitative and quantitative phenotyping in preparation for clinical trials.
    Li Q; Wang C; Zhang S; Fu Z; Jiao X; Jin ZB; Hejtmancik JF; Peng X
    Br J Ophthalmol; 2024 Jul; 108(8):1145-1153. PubMed ID: 37963713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.